NP001 ALS Trial Seeks Participants

NP001

Researchers are looking for people to participate in a phase 2 clinical trial, sponsored by Neuraltus Pharmaceuticals, that is designed to test whether the investigational drug NP001 slows progression of signs and symptoms in ALS.

Read More

Keeping Up the Momentum

Following the approval of three drugs in six months, new MDA grants push for more progress By Grace Pavlath, Ph.D., MDA Senior Vice President & Scientific Program Director What are the effects of steroids on muscle repair in patients with Duchenne muscular dystrophy (DMD)? How can gene therapy impact people with Charcot-Marie-Tooth disease (CMT)? Will . . .

Read More